Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

People Briefs: IOM President, Edwards Lifesciences, Quest Diagnostics, Advanced ICU Care

This article was originally published in The Gray Sheet

Executive Summary

Newly appointed IOM president is a Duke chancellor and Medtronic board member. Quest Diagnostics makes executive suite changes. Telemedicine firm Advanced ICU Care names chairman and CEO. More people briefs.

You may also be interested in...



Institute Of Medicine On 510(k) Review Program: Dump It

The Institute of Medicine committee charged with reviewing FDA's 510(k) device pre-market review program is urging the agency to ditch the 35-year-old program and start fresh.

People In Brief

LaViolette joins valve developer board: Former chief operating officer and soon-to-be former senior advisor to Boston Scientific Paul LaViolette last week joined the board of directors of privately held Direct Flow Medical, which is developing a minimally invasive aortic valve replacement system. Edwards Lifesciences has the only transcather valve product on the market (in Europe), but several other large firms, including Medtronic and Johnson & Johnson, are developing such products. LaViolette had been with Boston Scientific for 15 years, but is slated to leave the company at the end of the year following a reorganization announced in June (1"The Gray Sheet" June 9, 2008, p. 8)

Amneal Eyes Avastin And Praises $120m Biosimilar Development Savings

Amneal is close to a filed pipeline of three biosimilar products in the US, while furthering ambitions in the complex generics and 505(b)(2) space, management told the virtual J.P. Morgan Healthcare Conference.

Topics

Related Companies

UsernamePublicRestriction

Register

OM007016

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel